AP
TNGX icon

Antipodes Partners’s Tango Therapeutics TNGX Stock Holding History

Antipodes Partners’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.4K Sell
1,037
-585
-36% -$14.5K ﹤0.01% 126
2026
Q1 		$33.9K Sell
1,622
-2,891
-64% -$40.2K ﹤0.01% 112
2025
Q4 		$40K Buy
+4,513
New +$38.9K ﹤0.01% 109

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Antipodes Partners's TNGX Position: Q2 2026 in Review

Antipodes Partners reduced its Tango Therapeutics (TNGX) stake by 36% in Q2 2026, selling an estimated $14.5K and leaving 1,037 shares worth $32.4K. The position accounts for ﹤0.01% of the portfolio, ranked #126.

Antipodes Partners first reported a position in TNGX in Q4 2025 and has held it in 3 quarters since. The position peaked at $40K in Q4 2025. 248 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Antipodes Partners held 1,037 shares of Tango Therapeutics worth $32.4K as of Q2 2026.
  • Antipodes Partners sold 585 Tango Therapeutics shares in Q2 2026, an estimated $14.5K.
  • Tango Therapeutics made up ﹤0.01% of Antipodes Partners's portfolio in Q2 2026, its #126 holding.
  • Antipodes Partners first reported a position in Tango Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Antipodes Partners's Tango Therapeutics position peaked at $40K in Q4 2025.
  • 248 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.